FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2FOR2240-Logo2
  • Home
  • About
  • Projects
    • P1 Lymph-Transplant
    • P2 Modulators of LA
    • N1 Ocular GvHD
    • N2 ABCB5 & Pterygium
    • P4 Ocular Melanoma
    • P5 Myeloid Cells
    • P6 Microglia in AMD
    • P8 Uveitis
    • C1 Eye Imaging
    • C2 Management
    • Publication highlights
  • Team
    • Executive Board
    • Research Groups
    • Central Projects
    • Associated projects
    • Alumni
  • Links
  • Events
    • Guest lectures
    • Retreats
    • Symposium
  • News
✕

Visiting Professor Dr. Stern delights again

Urkundenübergabe an Herrn Michael E. Stern Ph. D., Augenklinik, v.l., Univ.-Prof. Dr. Claus Cursiefen, Michael E. Stern Ph. D., PD Dr. Philipp Steven, im CECAD

With clarity, warmth and humor, ocular immunologist Dr. Michael E. Stern mesmerized the audience with a lecture on “Aspects of aging and inflammation in dry eye disease” in his second visit to the University of Cologne. His talk was held on September 29th, 2015 in the CECAD lecture hall on the campus of the University of Cologne, right across the street from the newly renovated Eye Hospital, the main location of the Department of Ophthalmology at the University of Cologne. Dr. Stern, a long-standing giant in dry eye disease research, is currently an Adjunct Associate Professor of Ophthalmology at Baylor College of Medicine, Cullen Eye Institute in Houston, Texas and Co-Director of the IOBA Ocular Surface Disease Program at the University of Valladolid, Spain. While Vice President of Inflammation Research at Allergan Inc. in Irvine, California, Dr. Stern laid the groundwork for the development of topical ophthalmic CsA (Restasis®), the only FDA-approved therapy for dry eye, a common autoimmune-based ocular inflammatory disease. On September 28th, 2015, Dr. Stern met with the researchers of the DFG-funded research unit FOR2240 “Angiogenesis, lymphangiogenesis and cellular immunity in inflammatory diseases of the eye” in the group led by PD Dr. Philipp Steven, a principle investigator in the central project “Cologne Experimental Eye Imaging Center (CEE-IC)”, who invited Dr. Stern.

Dr. Stern’s talk provided a framework in which several major unknowns in the field of dry eye disease research could be coherently identified and understood in a larger context.

Pictured from left: Prof. Claus Cursiefen, Speaker of the FOR2240 and Director of the Department of Ophthalmology at the University of Cologne, Dr. Michael E. Stern, PD Dr. Philipp Steven

 

Related posts

January 7, 2023

Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface


Read more
December 15, 2022

Leonhard Klein-Preis for Prof. Matthaei


Read more
November 22, 2022

4th Shanghai-Cologne Scientific Symposium


Read more

News

  • Rare eye diseases: Eight million euros for research: Funding for four years
  • Dr. Sarah Barbara Zwingelberg, is awarded Belmonte Fellowship for research on the neurobiology of the ocular surface
  • Experimental Glaucoma Research Group awarded and funded
  • Leonhard Klein-Preis for Prof. Matthaei
  • 4th Shanghai-Cologne Scientific Symposium

More information

  • Publication highlights
  • Jobs
  • Contact
  • Impressum
  • Datenschutz

Newest publications

Supplemental Anti Vegf A-Therapy Prevents Rebound…(2020)


Bevacizumab Induces Upregulation of Keratin 3 and VEGFA in Human…(2020)


Immune reactions after modern lamellar (DALK, DSAEK, DMEK) versus conventional…(2020)


Contact

Esther Engel
Management Office
DFG Research Unit FOR2240
Department of Ophthalmology
University of Cologne
Kerpener Str. 62
50937 Cologne, Germany

www.for2240.de

Tel. +49 (0)221 478 32845
Fax. +49 (0)221 478 5094
esther.engel@uk-koeln.de

Partnerlogos

© 2021 FOR2240 | Online Marketing von Resulted Lübeck